Pierre Laneuville
Affiliations: | McGill University, Montreal, QC, Canada |
Area:
Medicine and Surgery, Oncology, Molecular BiologyGoogle:
"Pierre Laneuville"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Perusini MA, Novitzky-Basso I, Atenafu EG, et al. (2023) Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study. British Journal of Haematology |
| Banerji V, Anglin P, Christofides A, et al. (2020) Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia. Current Oncology (Toronto, Ont.). 27: e231-e245 |
| Daher-Reyes GS, Bence-Bruckler I, Busque L, et al. (2019) BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission Blood. 134: 2933-2933 |
| Kim DDH, Bence-Bruckler I, Busque L, et al. (2019) The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up Blood. 134: 1644-1644 |
| Berinstein N, Bence-Buckler I, Laneuville P, et al. (2019) SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Hematological Oncology. 37: 569-569 |
| Klil-Drori AJ, Yin H, Azoulay L, et al. (2018) Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia. Cancer |
| Grand'Maison F, Yeung M, Morrow SA, et al. (2018) Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. Neural Regeneration Research. 13: 1871-1874 |
| Hughes TP, Laneuville P, Rousselot P, et al. (2018) Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica |
| Grand'Maison F, Yeung M, Morrow SA, et al. (2018) Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. Current Medical Research and Opinion. 1-38 |
| Laneuville P. (2018) When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Current Treatment Options in Oncology. 19: 15 |